Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

is a once-daily formulation of the selective alpha-2A-adrenoceptor agonist guanfacine and was studied to determine if it provided control of ADHD symptoms throughout the day in children aged 6 to 17 years. The most commonly reported treatment-emergent adverse events were headache, somnolence, fatigue, upper abdominal pain and sedation


    Notes to editors


SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website: www.shire.com

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, inc
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 ... DMPI) ("DelMar" "the Company") today announced the filing of ... recently changed its fiscal year end to June 30th ... common stock on a national securities exchange in the ... filed with the United States Securities Exchange Commission can ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:8/30/2014)... Beach, Calif. (PRWEB) August 30, 2014 Insomnia ... Francis helps listeners understand how they unknowingly developed insomnia and ... have restful nights during. Tune in to the show ... The show airs live on August 30, and will ... more information on programming, go to DrCarolFrancisTalkRadio.com. , ...
(Date:8/30/2014)... 30, 2014 Hastings and Hastings, a ... located throughout Arizona is pleased to report having saved ... specific example among many cases where Hastings and Hastings ... to retain a greater portion of their settlement or ... providing a positive solution for Arizona car accident victims ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk along ... Wetumpka, Ala. "In order to help her be able to ... up with a way for her to use her crutches ... patent-pending Deezers to allow crutches to be used on uneven ... or canes at the beach. The device reduces the risk ...
(Date:8/30/2014)... WA (PRWEB) August 30, 2014 One of ... this era is the gluten-free diet. Originally meant for sufferers ... become a catchall for people who are looking to get ... However, not only is this kind of information erroneous, it ... health problems because of a drastic change in their ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2
... Unique off-label marketing case results in $425M ... government,s investigation,into Cephalon Inc.,s illegal marketing practices ... plea by the pharmaceutical company began,in January ... Ohio., The sales representative, Bruce Boise, ...
... Bear Bryant,Awards committee of the American Heart Association has ... has been named the,2009 winner of its, Lifetime Achievement ... Award at the Paul Bear,Bryant College Football Coaching Awards ... in Houston. The award recognizes excellence in,coaching on and ...
... pharmacy chain Walgreens has paid the United ... resolve allegations of falsely billing,the Medicaid program, ... submitted claims to Medicaid agencies in four ... both by Medicaid and by,private third-party insurance. ...
... More and more cancer patients are,looking for treatment ... of,life during difficult treatment regimens., ... at:, http://media.medialink.com/WebNR.aspx?story=35774 ) Philips Research is developing ... the effectiveness and reduce the side,effects of chemotherapy ...
... study also finds too many clinicians still using ... -- In children and teens, individual and group ... stress disorder (PTSD) and other trauma symptoms, say ... studies on the subject. , However, despite the ...
... it a “carrier of choice” for many in the medical device ... ... -- All medical devices share a critical need regardless of their ... the supply chain. For medical devices traveling to cross border ...
Cached Medicine News:Health News:Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon 2Health News:Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon 3Health News:Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon 4Health News:Barry Switzer to Receive Paul 'Bear' Bryant Lifetime Achievement Award 2Health News:Walgreens Pays U.S. $9.9 Million to Settle Medicaid Prescription Drug Allegations 2Health News:Cognitive Behavioral Therapy Best for Traumatized Youths 2Health News:Medical Device Producers Express Interest in Purolator USA's Express Service and Customer Service 2
... Craftsmanship have produced the finest ... Ocutek now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: